Protagonist Therapeutics, Inc. (PTGX)Healthcare | Biotechnology | Newark, United States | NasdaqGM
129.89 USD
-1.53
(-1.164%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:19 a.m. EDT
Protagonist Therapeutics is currently trading on a mix of strong momentum and speculative growth expectations. The stock has rallied significantly over the past eight years, outperforming the broader market, yet it remains unprofitable with negative earnings and a high price-to-sales ratio. The balance sheet is robust with substantial cash and negligible debt, which provides a safety net during the development phase. However, the valuation is stretched, and the lack of consistent profitability prevents a top-tier long-term rating. For the short term, technical indicators and options flow support a bullish case, but investors should remain cautious of the inherent risks associated with biotechnology development. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.074078 |
| MSTL_126 | 0.074301 |
| AutoARIMA | 0.077480 |
| AutoETS | 0.077630 |
| MSTL | 0.077975 |
| MSTL_90 | 0.098258 |
| MSTL_90_126 | 0.121151 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 23% |
| H-stat | 9.47 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.004 |
| Excess Kurtosis | 0.26 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.491 |
| Revenue per Share | 1.155 |
| Market Cap | 8,353,403,904 |
| Forward P/E | -205.25 |
| Beta | 1.79 |
| Profit Margins | -154.88% |
| Website | https://www.protagonist-inc.com |
As of July 11, 2026, 4:19 a.m. EDT: Implied volatility is elevated at the money, indicating heightened uncertainty. Call speculation is concentrated at strikes above the current price, with notable new volume entering at the 120, 135, and 140 levels, suggesting bets on further upside. Conversely, put writers are establishing significant protection at lower strikes, creating a floor around the 80 to 90 range.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.379504 |
| Address1 | 7,707 Gateway Boulevard |
| Address2 | Suite 140 |
| All Time High | 141.1 |
| All Time Low | 4.47 |
| Ask | 160.97 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 1,074,560 |
| Average Daily Volume3 Month | 722,652 |
| Average Volume | 722,652 |
| Average Volume10Days | 1,074,560 |
| Beta | 1.791 |
| Bid | 92.34 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 10.206 |
| City | Newark |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 129.89 |
| Current Ratio | 17.756 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 131.36 |
| Day Low | 125.3225 |
| Debt To Equity | 1.491 |
| Display Name | Protagonist Therapeutics |
| Earnings Timestamp | 1,778,011,200 |
| Earnings Timestamp End | 1,778,011,200 |
| Earnings Timestamp Start | 1,778,011,200 |
| Ebitda | -141,016,992 |
| Ebitda Margins | -1.90401 |
| Enterprise To Ebitda | -55.422 |
| Enterprise To Revenue | 105.524 |
| Enterprise Value | 7,815,394,304 |
| Eps Current Year | 4.18581 |
| Eps Forward | -0.63283 |
| Eps Trailing Twelve Months | -1.81 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 109.1736 |
| Fifty Day Average Change | 20.7164 |
| Fifty Day Average Change Percent | 0.1897565 |
| Fifty Two Week Change Percent | 137.9504 |
| Fifty Two Week High | 141.1 |
| Fifty Two Week High Change | -11.210007 |
| Fifty Two Week High Change Percent | -0.07944725 |
| Fifty Two Week Low | 50.485 |
| Fifty Two Week Low Change | 79.405 |
| Fifty Two Week Low Change Percent | 1.5728434 |
| Fifty Two Week Range | 50.485 - 141.1 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,470,922,200,000 |
| Float Shares | 52,492,872 |
| Forward Eps | -0.63283 |
| Forward P E | -205.2526 |
| Free Cashflow | -77,664,624 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 131 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 1.0 |
| Gross Profits | 74,063,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00714 |
| Held Percent Institutions | 1.25335 |
| Implied Shares Outstanding | 64,311,373 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. |
| Long Name | Protagonist Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 8,353,403,904 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_129263324 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -114,711,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 8,353,404,238 |
| Number Of Analyst Opinions | 13 |
| Open | 131.36 |
| Operating Cashflow | -116,635,000 |
| Operating Margins | -0.064720005 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 510 474 0170 |
| Pre Market Change | 0.009994507 |
| Pre Market Change Percent | 0.007694593 |
| Pre Market Price | 129.9 |
| Pre Market Time | 1,784,021,999 |
| Previous Close | 131.42 |
| Price Eps Current Year | 31.03103 |
| Price Hint | 2 |
| Price To Book | 12.726827 |
| Price To Sales Trailing12 Months | 112.78781 |
| Profit Margins | -1.5488299 |
| Quick Ratio | 17.509 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.38462 |
| Region | US |
| Regular Market Change | -1.53 |
| Regular Market Change Percent | -1.16421 |
| Regular Market Day High | 131.36 |
| Regular Market Day Low | 125.3225 |
| Regular Market Day Range | 125.3225 - 131.36 |
| Regular Market Open | 131.36 |
| Regular Market Previous Close | 131.42 |
| Regular Market Price | 129.89 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 541,006 |
| Return On Assets | -0.1237 |
| Return On Equity | -0.17063 |
| Revenue Growth | 0.99 |
| Revenue Per Share | 1.155 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 64,311,373 |
| Shares Percent Shares Out | 0.1196 |
| Shares Short | 7,691,347 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 7,410,849 |
| Short Name | Protagonist Therapeutics, Inc. |
| Short Percent Of Float | 0.1391 |
| Short Ratio | 8.88 |
| Source Interval | 15 |
| State | CA |
| Symbol | PTGX |
| Target High Price | 145.0 |
| Target Low Price | 100.0 |
| Target Mean Price | 120.53846 |
| Target Median Price | 118.0 |
| Total Cash | 547,785,984 |
| Total Cash Per Share | 8.518 |
| Total Debt | 9,776,000 |
| Total Revenue | 74,063,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.81 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 92.24255 |
| Two Hundred Day Average Change | 37.647446 |
| Two Hundred Day Average Change Percent | 0.40813532 |
| Type Disp | Equity |
| Volume | 541,006 |
| Website | https://www.protagonist-inc.com |
| Zip | 94,560 |